ADVERTISEMENT

Moderna

Pharmaceutical company producing COVID-19 vaccine

Moderna, Inc. is a company in Cambridge, Massachusetts, specializing in RNA therapeutics, particularly mRNA vaccines. Their COVID-19 vaccine, Spikevax, is their main product. They have numerous vaccine candidates in clinical trials for diseases like influenza, HIV, and cancer, as well as a cell therapy-based treatment for heart failure and regenerative medicine for myocardial ischemia.

Related

AstraZeneca Pfizer COVID-19 Novartis Humira Small Modular Reactor Amgen Elevance Health Johnson & Johnson CRISPR

Timeline

Saint Mary’s isolation hospital during the influenza pandemic

Documentation of the operations of Saint Mary’s isolation hospital during the 1918 influenza pandemic.

The Doctors Mayo

A book written by Clapesattle H. in 1941 about The Doctors Mayo, founders of the Mayo Clinic.

Moderna Founded

In spring 2010, Moderna was founded when Noubar Afeyan met with Bob Langer to discuss using mRNA for reprogramming cells. This marked the beginning of Moderna's journey to explore the potential of mRNA in medicine.

Flagship's VentureLabs filed provisional patents

In July and October 2010, Flagship's VentureLabs group filed provisional patents, marking a significant step in their innovation process.

Stéphane Bancel joined Moderna's board of directors

In March 2011, Stéphane Bancel, who previously served as the Chief Executive Officer of bioMérieux SA, joined Moderna's board of directors, bringing valuable expertise to the company.

Stéphane Bancel became CEO of Moderna

In October 2011, Stéphane Bancel assumed the role of CEO at Moderna, taking on a key leadership position within the company.

Moderna Raises $40 Million

In December 2012, Moderna raised $40 million in funding, further supporting its mRNA therapeutics platform.

Partnership with AstraZeneca

In March 21, 2013, Moderna signed a groundbreaking $240 million partnership with AstraZeneca, a pivotal moment as it was the largest investment in untested drugs by a pharmaceutical company.

Creation of Onkaido Therapeutics

On January 14, 2014, Moderna established Onkaido Therapeutics, focusing on mRNA-based oncology treatments.

Development of Moderna's mRNA vaccine platform

Moderna's vaccine platform is created, which involves inserting synthetic nucleoside-modified messenger RNA (modRNA) into human cells using lipid nanoparticles to elicit immune responses.

Stéphane Bancel becomes CEO of Moderna Therapeutics

Stéphane Bancel, with a background in sales and operations, takes on the role of CEO at Moderna Therapeutics, a biotech startup aiming to revolutionize medicine by converting human cells into drug factories.

Highly Placed Executives Resignations at Moderna

Several top executives, including heads of finance, technology, manufacturing, and science, have resigned from Moderna in the past four years. In the last 12 months, leaders of Moderna's cancer and rare disease programs also resigned, despite the company's successful fundraising efforts.

Moderna IPO Exceeds Revised Goal

Moderna's Initial Public Offering (IPO) on December 7 surpasses the revised target of $600 million by approximately $4.3 million, valuing the company at around $7.5 billion.

Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019

Moderna announced its plans to showcase data from two prophylactic mRNA vaccines at IDWeek 2019, highlighting its innovative research in the field.

Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)

Moderna's Propionic Acidemia Program, involving mRNA-3927, was granted Fast Track Designation by the FDA, expediting its development process.

Moderna Named Top Employer by Science for Fifth Consecutive Year

Moderna was recognized as a leading employer in the scientific community for the fifth year in a row by Science magazine.

François Nader, M.D., Joins Moderna’s Board of Directors

François Nader, M.D., became a member of Moderna's Board of Directors, bringing his expertise and experience to the company's leadership.

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Moderna reported encouraging results from the interim analysis of Phase 1 clinical trial data for its mRNA vaccine, mRNA-1273, designed to combat the novel coronavirus.

Supply Agreement with U.S. Government for COVID-19 Vaccine

On August 26, 2020, Moderna announced a supply agreement with the U.S. government for the initial 100 million doses of the COVID-19 vaccine.

Publication of Older Adults Phase 1 Data

On September 29, 2020, the data from the Phase 1 trial involving older adults was published.

Completion of Phase 3 COVE Study Enrollment

On November 15, 2020, the enrollment for the Phase 3 COVE study was completed.

mRNA-1273 Trials Completion

On November 30, 2020, Moderna completed trials confirming the vaccine candidate's effectiveness in preventing severe cases of COVID-19.

Moderna COVID-19 Vaccine Approval

Moderna's COVID-19 vaccine received emergency use authorization from the FDA on December 18, 2020.

Emergency Use Authorization for mRNA-1273

On December 18, 2020, mRNA-1273 received emergency use authorization in the United States, marking a significant milestone in Moderna's COVID-19 vaccine development.

mRNA-1273 Authorized in the UK

On January 8, 2021, mRNA-1273 was authorized for use in the United Kingdom, expanding the reach of Moderna's COVID-19 vaccine.

The Biological Century Essay

Doug Cole's essay explores the concept of the Biological Century and its implications.

Capitalizing on “Biotech’s Moment” Essay

Stephen Berenson's essay discusses seizing the opportunity in the biotech field to create significant value.

Moderna Company History

A brief overview of the history of Moderna, a biotechnology company known for its involvement in the development of Covid-19 vaccines.

Spikevax and Moderna COVID-19 Vaccine Approval

The U.S. Food and Drug Administration approved the Spikevax and Moderna COVID-19 vaccines. This decision was made on February 11, 2022.

2023 Flagship CEO Chat with Stéphane Bancel

A CEO chat featuring Stéphane Bancel, the CEO of Moderna, discussing future plans and strategies.

Stephen Hoge Named 2023 Pioneering Leader of the Year

Flagship Pioneering names Stephen Hoge as the 2023 Pioneering Leader of the Year, recognizing his contributions to the field.

End of the Timeline
Moderna

Popular

Southeast Asian city-state known for its economy

Short-form video hosting service

TikTok

Lockheed Martin

American aerospace and defense corporation

French professional footballer for Paris Saint-Germain and France.

American UFC commentator, podcaster, comedian, actor

ADVERTISEMENT

Recently Added

Brighton & Hove Albion F.C.

English professional football club in Brighton and Hove

Professional football club in West London

Burnley F.C. is a football club in Lancashire

A.F.C. Bournemouth

Football club with roots dating back to 1890

Gustave Courbet

French Realism painter and innovator

ADVERTISEMENT